182 related articles for article (PubMed ID: 12473601)
1. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer.
Climent J; Martinez-Climent JA; Blesa D; Garcia-Barchino MJ; Saez R; Sánchez-Izquierdo D; Azagra P; Lluch A; Garcia-Conde J
Clin Cancer Res; 2002 Dec; 8(12):3863-9. PubMed ID: 12473601
[TBL] [Abstract][Full Text] [Related]
2. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer.
Dellas A; Torhorst J; Schultheiss E; Mihatsch MJ; Moch H
Clin Cancer Res; 2002 May; 8(5):1210-6. PubMed ID: 12006540
[TBL] [Abstract][Full Text] [Related]
3. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization.
Günther K; Merkelbach-Bruse S; Amo-Takyi BK; Handt S; Schröder W; Tietze L
J Pathol; 2001 Jan; 193(1):40-7. PubMed ID: 11169514
[TBL] [Abstract][Full Text] [Related]
4. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization.
Rennstam K; Ahlstedt-Soini M; Baldetorp B; Bendahl PO; Borg A; Karhu R; Tanner M; Tirkkonen M; Isola J
Cancer Res; 2003 Dec; 63(24):8861-8. PubMed ID: 14695203
[TBL] [Abstract][Full Text] [Related]
5. Molecular cytogenetics of primary breast cancer by CGH.
Tirkkonen M; Tanner M; Karhu R; Kallioniemi A; Isola J; Kallioniemi OP
Genes Chromosomes Cancer; 1998 Mar; 21(3):177-84. PubMed ID: 9523192
[TBL] [Abstract][Full Text] [Related]
6. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
[TBL] [Abstract][Full Text] [Related]
7. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
8. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
[TBL] [Abstract][Full Text] [Related]
9. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
10. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer in young women (< or = 35 years): Genomic aberrations detected by comparative genomic hybridization.
Weber-Mangal S; Sinn HP; Popp S; Klaes R; Emig R; Bentz M; Mansmann U; Bastert G; Bartram CR; Jauch A
Int J Cancer; 2003 Nov; 107(4):583-92. PubMed ID: 14520696
[TBL] [Abstract][Full Text] [Related]
12. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
13. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
14. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer.
Stange DE; Radlwimmer B; Schubert F; Traub F; Pich A; Toedt G; Mendrzyk F; Lehmann U; Eils R; Kreipe H; Lichter P
Clin Cancer Res; 2006 Jan; 12(2):345-52. PubMed ID: 16428471
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors.
Hermsen MA; Baak JP; Meijer GA; Weiss JM; Walboomers JW; Snijders PJ; van Diest PJ
J Pathol; 1998 Dec; 186(4):356-62. PubMed ID: 10209483
[TBL] [Abstract][Full Text] [Related]
18. Genomic aberrations in carcinomas of the uterine corpus.
Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients.
Seute A; Sinn HP; Schlenk RF; Emig R; Wallwiener D; Grischke EM; Hohaus S; Döhner H; Haas R; Bentz M
Int J Cancer; 2001 Jul; 93(1):80-4. PubMed ID: 11391625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
